A Picture of Prostate Cancer in Europe
HAMBURG-The Federation of European Cancer Societies released information on prostate cancer in Europe at its biennial European Cancer Conference (ECCO 9).
HAMBURGThe Federation of European Cancer Societies released information on prostate cancer in Europe at its biennial European Cancer Conference (ECCO 9).
- In Europe, one man in 11 is diagnosed with prostate cancer, which accounts for 13% of all new cancer diagnoses and almost 9% of cancer deaths.
- The death rate tends to be highest in northern European countries and lowest in southern and eastern Europe.
- Death rates from prostate cancer have risen dramatically in recent years, probably because of the increasing number of elderly men in the population. In England and Wales, for example, there were 4,313 deaths attributed to prostate cancer in 1974, compared with 8,735 in 1992, a 103% increase in only 17 years.
Articles in this issue
Panel Recommends Thalidomide Approval For Leprosy, Studies in Cancer Are Reported
Toremifene, Tamoxifen Equivalent in Advanced Breast Cancer
Fluorescence ‘LIFE’ Images Spot Occult Lung Cancer Lesions
The Issue That Won’t Go Away: Screening Mammography
News in Brief...
Concurrent Better Than Sequential Chemo-RT in NSCLC
Consumer Version of Merck & Co’s Famous Manual Is Available
A Talk With Dr. Richard Klausner, Head of the NCI
Age Is a Factor in Survival of SqCC of the Head and Neck
Symptom-Based Staging of Head & Neck Cancer
President Asks Congress to Toughen Tobacco Settlement
Efficacy of HIV ‘Cocktail’ May Spur Efforts for National HIV Reporting
Paxene Wins ODAC Backing for Use In AIDS-Associated Kaposi’s Sarcoma
Multiple Myeloma Patients Needed for Trial of MDR Reverser
University of Pittsburgh Apologizes to Dr. Bernard Fisher
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025Podcast
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
